These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 6414080)

  • 21. A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate.
    Hull RG; Morgan SH; Parke AL; Childs L; Goldman M; Hughes GR
    Int J Clin Pharmacol Res; 1984; 4(6):395-401. PubMed ID: 6442711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of auranofin dose regimen change upon cell-associated gold in rheumatoid arthritic patients.
    Walz DT; Griswold DE; DiMartino MJ; Bumbier EE
    J Rheumatol; 1981; 8(5):829-32. PubMed ID: 6796684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of sodium aurothiomalate and triethyl phosphine gold to cause renal tubular injury in rheumatoid arthritis: implications for the aetiology of gold-related nephropathy.
    Crisp AJ; Coughlan RJ; Clark B; Mackintosh D; Panayi GS; Sweny P; Hopper J; Varghese Z
    Clin Rheumatol; 1983 Sep; 2(3):273-6. PubMed ID: 6432404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial experience with oral gold salts in the treatment of rheumatoid arthritis in patients followed up for one year.
    Lignère GC; Giavarini S; Longatti S
    J Int Med Res; 1984; 12(3):193-7. PubMed ID: 6428946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurotoxicity following a very high dose of oral gold (auranofin).
    Gambari P; Ostuni P; Lazzarin P; Tavolato B; Todesco S
    Arthritis Rheum; 1984 Nov; 27(11):1316-7. PubMed ID: 6093822
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study.
    van Riel PL; van de Putte LB; Gribnau FW; Macrae KD
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():51-6. PubMed ID: 6432414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 12-month comparative trial of auranofin and D-penicillamine in rheumatoid arthritis.
    Felix-Davies DD; Stewart AM; Wilkinson BR; Bateman JR; Delamere JP
    Am J Med; 1983 Dec; 75(6A):138-41. PubMed ID: 6419596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An oral formulation of gold for the treatment of rheumatoid arthritis.
    Meyers OL; Klemp P
    S Afr Med J; 1981 Jun; 59(27):969-71. PubMed ID: 6787721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Auranofin: 1 mg or 9 mg? The search for the appropriate dose.
    Calin A; Saunders D; Bennett R; Jacox R; Kaplan D; O'Brien W; Paulus HE; Roth S; Weiss T
    J Rheumatol Suppl; 1982; 8():146-8. PubMed ID: 6813476
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate.
    Lewis D; Capell HA
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():83-96. PubMed ID: 6432418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bronchiolitis in a rheumatoid arthritis patient receiving auranofin.
    O'Duffy JD; Luthra HS; Unni KK; Hyatt RE
    Arthritis Rheum; 1986 Apr; 29(4):556-9. PubMed ID: 3085683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of auranofin, an oral chrysotherapeutic agent.
    Delafuente JC; Osborn TG
    Clin Pharm; 1984; 3(2):121-7. PubMed ID: 6426843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Auranofin: more than just oral gold.
    Waller ES
    Clin Pharm; 1984; 3(2):195. PubMed ID: 6426845
    [No Abstract]   [Full Text] [Related]  

  • 34. Worldwide clinical experience with auranofin.
    Morris RW; Cole DS; Horton J; Heuer MA; Pietrusko RG
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():105-11. PubMed ID: 6432408
    [No Abstract]   [Full Text] [Related]  

  • 35. Gold concentrations and toxicity during oral gold treatment with auranofin.
    Sharma RP; Smillie J; Palmer DG
    Pharmacology; 1985; 30(2):115-20. PubMed ID: 3919401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteinuria in gold-treated rheumatoid arthritis.
    Katz WA; Blodgett RC; Pietrusko RG
    Ann Intern Med; 1984 Aug; 101(2):176-9. PubMed ID: 6430141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multicenter double-blind comparison of auranofin and Tauredon].
    Kaik B; Bröll H
    Wien Klin Wochenschr Suppl; 1984; 156():33-40. PubMed ID: 6442055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ulcerative colitis caused by oral gold therapy in rheumatoid arthritis].
    Bross-Bach U; Saal JG; Hartmann F; Müller CA; Waller HD
    Z Rheumatol; 1987; 46(4):201-4. PubMed ID: 3118590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Auranofin. Mechanism of action, pharmacokinetics and clinical use. Comparison with injectable gold salts].
    Chamouard JM; Clerc D; Bisson M; Medicis P; Massias P
    Rev Rhum Mal Osteoartic; 1985 Apr; 52(4):277-82. PubMed ID: 3923604
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis.
    Furst DE
    Pharmacotherapy; 1983; 3(5):284-98. PubMed ID: 6417628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.